Loading exclusive…
$KPTI: Q2 Loss Widens on Cash Burn; SNDA Timeline Key
Karyopharm reports a deeper-than-expected Q2 loss, signaling accelerated cash consumption ahead of the critical myelofibrosis sNDA submission.
Key Points
- Q2 EPS miss of 63% vs consensus ($2.32 vs ($1.53))
- Accelerated cash burn linked to myelofibrosis sNDA prep
- Market cap down ~3.3% on session on loss widening
- Focus shifts to cash runway and sNDA submission timeline
What To Watch
- Management commentary on sNDA submission date
- Updated cash runway and potential need for capital raise
- Any updates on partnership discussions for myelofibrosis